次世代がん診断の世界市場規模、シェア、成長分析、用途別、がんタイプ別-産業予測、2024～2031年

次世代がん診断の世界市場規模は2022年に99億米ドルと評価され、予測期間（2024～2031年）のCAGRは17.8%で、2023年の116億6,000万米ドルから2031年には432億5,000万米ドルに成長する展望です。

従来のラボ試験は、迅速なポイントオブケア試験に取って代わられつつあります。診断キット、試薬、機器など、技術的に洗練されたさまざまな商品が商品化されることが予想されるため、このシフトは市場拡大の一助となると考えられます。予測期間中、コンパニオン診断の開発が進み、より強化されたテーラーメイドの遺伝子治療が提供されるようになるため、市場規模の高い成長機会が見込まれます。Global Cancer Observatory 2021の数字によると、2020年には世界で約8万3,000例のホジキンリンパ腫と54万4,000例の非ホジキンリンパ腫が報告されました。さらに、2020年には白血病の症例が47万4,000件以上、多発性骨髄腫の症例が17万6,000件以上報告されています。世界保健機関（WHO）によると、がんは世界で2番目に多い死因であり、年間960万人が死亡していると推定されています。がんの有病率の上昇に伴い、より正確で効率的な診断機器がますます必要となってきています。市場開拓は、新しいがんバイオマーカーや診断を開発する様々な業界企業によって支えられています。がん診断は、がんの早期発見を可能にし、治療の選択肢を向上させる。次世代がん診断により、病気の発見がより正確になり、価格もリーズナブルになります。研究者たちは常に、がん診断のための新しい、最小限の侵襲的方法を生み出そうとしています。毎年、37万5,000人以上のがん患者が新たに報告され、致死率は44％を超えています。

目次

エグゼクティブサマリー

• 市場概要
• 繁栄と衰退

調査手法

• 情報調達
• セカンダリとプライマリデータソース
• 市場規模の推定
• 市場の前提条件と制限

親市場の分析

• 市場概要
• 市場規模
• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題

主要市場の考察

• 技術分析
• 価格分析
• サプライチェーン分析
• バリューチェーン分析
• 市場のエコシステム
• IP分析
• 貿易分析
• スタートアップ分析
• 原材料の分析
• イノベーションマトリクス
• パイプライン製品の分析
• マクロ経済指標
• 主要投資の分析
• 主要成功要因
• 競合の程度

市場力学と展望

• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
• 規制情勢
• ポーターの分析
• 将来の混乱についての特別な考察

次世代がん診断の世界市場：用途別

• 市場概要
• バイオマーカーの開発
• CTC分析
• プロテオーム解析
• エピジェネティック解析
• 遺伝子解析

次世代がん診断の世界市場：がんタイプ別

• 市場概要
• 肺
• 胸
• 結腸直腸
• 子宮頸部
• その他

次世代がん診断の世界市場規模：地域別

• 市場概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • その他の欧州地域
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他のアジア太平洋
• ラテンアメリカ
  • ブラジル
  • その他のラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ地域

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング（2021年）
• 主要市場企業が採用した戦略
• 主要成功戦略
• 市場における最近の活動
• 主要企業の市場シェア（2021年）

主要企業プロファイル

• Abbott Laboratories
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd.
• GE Healthcare
• Grail, Inc.
• Guardant Health, Inc.
• Hologic, Inc.
• Illumina, Inc.
• Merck & Co., Inc.
• Myriad Genetics, Inc.
• NanoString Technologies, Inc.
• Natera, Inc.
• NeoGenomics, Inc.
• Qiagen N.V.
• Quest Diagnostics Incorporated
• Siemens Healthineers AG
• Sysmex Corporation
• Thermo Fisher Scientific, Inc.
• Veracyte, Inc.

Global Next Generation Cancer Diagnostics Market size was valued at USD 9.90 billion in 2022 and is poised to grow from USD 11.66 billion in 2023 to USD 43.25 billion by 2031, at a CAGR of 17.8% during the forecast period (2024-2031).

Traditional laboratory testing is being replaced by rapid point-of-care testing. This shift will aid in market expansion as it is anticipated that a wide range of technologically sophisticated goods, such as diagnostic kits, reagents, and devices, would be commercialized. Over the course of the forecast period, the market is expected to witness high-value growth opportunities as a result of the increased development of companion diagnostics for their use in providing enhanced and tailored genetic therapy. Global Cancer Observatory 2021 figures show that around 83,000 cases of Hodgkin lymphoma and 544,000 cases of non-Hodgkin lymphoma were reported worldwide in 2020. Furthermore, more than 474,000 cases of leukemia and more than 176,000 cases of multiple myeloma were reported in 2020. According to the World Health Organization, cancer is the second most prevalent cause of death globally, accounting for an estimated 9.6 million deaths annually. More accurate and efficient diagnostic instruments are becoming more and more necessary as the prevalence of cancer rises. Market expansion is being aided by the various industry players developing new cancer biomarkers and diagnostics. Cancer diagnostics enable early cancer detection, which improves treatment options. Next-generation cancer diagnosis makes illness detection more precise and reasonably priced. Researchers are constantly attempting to create new, minimally intrusive methods for cancer diagnosis. Annually, there are more than 375,000 new cases of cancer reported, with a fatality rate above 44%.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Next Generation Cancer Diagnostics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Next Generation Cancer Diagnostics Market Segmental Analysis

The cancer type, function, location, and application are the segments that make up the global market for next-generation cancer diagnostics. The market is divided into five application segments: proteomic analysis, ctc analysis, genetic analysis, epigenetic analysis, and biomarker development. The market is divided into lung, breast, colorectal, cervical, and other cancer types. The market is divided into segments based on function, including prognosis, cancer screening, companion diagnostics, therapeutic monitoring, and risk analysis. The market is divided into Latin America, Middle East and Africa, Asia Pacific, North America, and Europe.

Drivers of the Global Next Generation Cancer Diagnostics Market

The market for next-generation cancer diagnostics is expanding due to the growing need for tailored medications. Personalized medicine refers to the process of customizing a patient's course of care according to their genetic profile and other attributes. Patients who are most likely to benefit from individualized therapy can be identified with the use of next-generation cancer diagnostic techniques.

Restraints in the Global Next Generation Cancer Diagnostics Market

These difficulties stem from the vagueness of reimbursement guidelines and the glacial speed at which they are being developed. This ambiguity may hinder the uptake and application of these novel technologies, making it challenging for patients and healthcare professionals to defend the expenses of these examinations. There are significant differences in the reimbursement policies for next-generation cancer diagnostics between various nations, areas, and healthcare systems. It is not widely agreed upon how to pay for these new technologies, and in many cases, these policies are currently being created.

Market Trends of the Global Next Generation Cancer Diagnostics Market

For the diagnosis of cancer and the tracking of treatment, liquid biopsy assays have become a viable substitute for conventional tissue biopsy testing. To find cancer cells and other indicators, these tests analyze a patient's blood, urine, or other body fluids. Compared to conventional biopsy examinations, liquid biopsy procedures can yield more frequent and reliable results while requiring less financial and invasive resources. As a result, liquid biopsy tests are becoming more and more popular in the market, and numerous businesses have invested in their development.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Next Generation Cancer Diagnostics Market by Application

• Market Overview
• Biomarker Development
• CTC Analysis
• Proteomic Analysis
• Epigenetic Analysis
• Genetic Analysis

Global Next Generation Cancer Diagnostics Market by Cancer Type

• Market Overview
• Lung
• Breast
• Colorectal
• Cervical
• Others

Global Next Generation Cancer Diagnostics Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grail, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NanoString Technologies, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natera, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeoGenomics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics Incorporated
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Veracyte, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments